Novartis AG ADR (NVS)vsSarepta Therapeutics Inc (SRPT)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
SRPT
Sarepta Therapeutics Inc
$20.67
-1.90%
HEALTHCARE · Cap: $2.18B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 2474% more annual revenue ($56.58B vs $2.20B). NVS leads profitability with a 23.9% profit margin vs -32.5%. NVS appears more attractively valued with a PEG of 2.48. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
SRPT
Hold47
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Intrinsic value data unavailable for SRPT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Earnings expanding 2664.0% YoY
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Weak financial health signals
Expensive relative to growth rate
ROE of -53.5% — below average capital efficiency
Revenue declined 32.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : SRPT
The strongest argument for SRPT centers on EPS Growth, Price/Book.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : SRPT
The primary concerns for SRPT are Piotroski F-Score, PEG Ratio, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while SRPT is a turnaround play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.52 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 47/100), backed by strong 23.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Sarepta Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?